Superworth

Envoy Medical COCH

Medical - Instruments & Supplies, Healthcare
$6.65
+0.30%
Market cap
$51.3M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
n/m
a sliver of sales
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$207K
−7% on a year ago
Net margin
n/m
outside −100% to 100%
Free cash flow yield
n/m
not a meaningful number

Envoy Medical's trailing earnings are negative, so it has no PE. Revenue was $207K over the last twelve months, down 7% on a year earlier.

Charts

Financials

Income statement for COCH, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$80K+40%$95K+375%$59K−24%$68K+8%$56K−30%$42K−56%$46K−22%$78K+15%$42K−25%$75K+79%$39K−15%$51K−35%
Cost of revenue$189K+78%$234K+55%$153K−13%$245K+51%$187K−1%$157K−33%$226K+48%$234K−5%$203K+9%$211K+34%$313K+39%$278K+19%
Gross profit−$109K+122%−$139K+6%−$94K−3%−$177K+79%−$131K+20%−$115K−17%−$180K+92%−$156K−12%−$161K+23%−$136K+18%−$274K+52%−$227K+46%
R&D$1.9M+98%$3.1M+112%$2.4M+23%$2.6M+20%$2.8M+49%$2.5M−19%$2.7M+16%$2.5M−4%$2.7M−2%$4.6M+84%$3.6M+33%$3.1M+26%
SG&A$1.4M+76%$1.9M+320%$2.4M+39%$2.1M−7%$2.1M+46%$2M+5%$2.2M−10%$2.4M+17%$2.8M+37%$1.7M−14%$2M−6%$2.2M−9%
−$3.4M+89%−$6.7M+131%−$4.9M+30%−$4.9M+8%−$5M+47%−$4.5M−32%−$5.1M+5%−$5.1M+5%−$5.7M+15%−$6.4M+40%−$6M+17%−$5.6M+10%
Interest expensen/an/a$36K$132K$264K$384K$495K+1275%$624K+373%$471K+78%$0n/an/a
Pre-tax incomen/an/an/an/an/an/an/an/an/an/an/an/a
n/an/an/an/an/an/an/an/an/an/an/an/a
Net income$1.6M−$4.9M+144%−$6.3M−53%−$3.9M−70%−$6M−$4.6M−6%−$5M−20%−$5.7M+44%−$6.5M+9%−$6.6M+43%−$4.4M−13%−$6M+5%
$1.30−$2.50+400%−$4.10−69%−$2.90−78%−$3.90−$4.00+60%−$2.90−29%−$3.20+10%−$3.50−10%−$2.70−33%−$0.80−72%−$0.70−78%
1.1M+11%2M+94%1.9M+84%1.9M+84%1.9M+66%1.9M−2%2.1M+15%2.1M+15%2.2M+17%2.8M+47%6.9M+223%10.4M+387%

Gross profit: 16 periods, Q3 FY22 to Q2 FY26: not printed by the filing, worked out from its own lines.

EPS, diluted: 6 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 4 periods, Q4 FY21 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Instruments & Supplies nearest Envoy Medical's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
COCHEnvoy Medical$51.3Mn/m35.1×n/m−7%n/m
APTAlpha Pro Tech$56.3M13.5×14.8×0.9×+6%6.8%
NEPHNephros$35.2M20.3×28.3×1.7×+24%8.4%
KEQUKewaunee Scientific$96.7M12.1×13.6×0.3×+5%3.0%
PDEXPro DEX$184.5M15.9×16.5×2.3×+13%15.1%
UTMDUtah Medical Products$224.6M21.5×20.9×6.2×−7%29.0%
INFUInfuSystem$275.7M33.8×43.5×1.9×+2%6.0%
EMBCEmbecta$350.7M4.2×11.6×0.3×−8%8.6%
Peer median$184.5M15.9×16.5×1.7×+5%8.4%

More on Envoy Medical

Each number over time

Its groups

About

Industry
Medical - Instruments & Supplies
Sector
Healthcare

Valuation data, not investment advice. Prices as of .